Related Experiment Video
Updated: Mar 2, 2026
10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
12.5K
The Enhanced International Prognostic Index for Diffuse Large B-cell Lymphoma
Yan Yang1, Lanlan Wang1, Yanna Ma1
1Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
The American Journal of the Medical Sciences
|May 16, 2017
Summary
The enhanced International Prognostic Index (NCCN-IPI) accurately predicts outcomes for Asian patients with diffuse large B-cell lymphoma (DLBCL) in the rituximab era. This prognostic tool is particularly valuable for identifying high-risk individuals, improving clinical decision-making.
Area of Science:
- Hematology
- Oncology
- Clinical Prognostics
Background:
- Diffuse large B-cell lymphoma (DLBCL) is a significant hematologic malignancy.
- Prognostic indices are crucial for guiding treatment strategies in DLBCL.
- The rituximab era has improved outcomes, necessitating updated prognostic tools.
Purpose of the Study:
- To evaluate the prognostic performance of the NCCN-IPI in Asian DLBCL patients.
- To compare NCCN-IPI with established indices like IPI and R-IPI.
- To assess the utility of NCCN-IPI for stratifying high-risk DLBCL patients.
Main Methods:
- Retrospective analysis of 176 newly diagnosed DLBCL patients.
- Evaluation of overall survival (OS) and progression-free survival (PFS).
- Comparison of prognostic discrimination by NCCN-IPI, IPI, and R-IPI.
Main Results:
- NCCN-IPI demonstrated significant discrimination across risk groups for both OS and PFS (P < 0.001).
- At 3 years, OS was 73% and PFS was 65% for the cohort.
- NCCN-IPI showed a wider range of outcomes, especially differentiating high-risk from high-intermediate risk groups.
Conclusions:
- The NCCN-IPI is a clinically valuable prognostic index for DLBCL patients treated with rituximab.
- NCCN-IPI provides effective risk stratification, particularly for high-risk patient populations.
- This index aids in personalized treatment approaches for DLBCL.
